OKUR · Insider Trading
OnKure Therapeutics, Inc. Class A Common Stock
Every open-market purchase and sale reported by OKUR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Nicholas A Saccomano | President and CEO | Sell | −87 | −$259 |
| 2026-09-23 | Jason A. Leverone | Chief Financial Officer | Sell | −302 | −$898 |
| 2026-08-13 | Isaac Manke | Director | — | — | — |
| 2026-08-11 | Liam Ratcliffe | Director | A | +22,350 deriv. | — |
| 2026-08-11 | Michael G Grey | Director | A | +22,350 deriv. | — |
| 2026-08-11 | Andrew John Phillips | Director | A | +22,350 deriv. | — |
| 2026-08-11 | Isaac Manke | Director | MIXED | +300,000 deriv. | — |
| 2026-08-11 | Samuel Agresta | Chief Medical Officer | MIXED | +50,000 deriv. | — |
| 2026-08-11 | Edward T Mathers | Director | A | +22,350 deriv. | — |
| 2026-08-11 | Jason A. Leverone | Chief Financial Officer | MIXED | +50,000 deriv. | — |
| 2026-08-11 | Dylan Hartley | Chief Scientific Officer | MIXED | +50,000 deriv. | — |
| 2026-08-11 | Nicholas A Saccomano | President and CEO | MIXED | +150,000 deriv. | — |
| 2026-08-11 | Valerie Malyvanh Jansen | Director | A | +22,350 deriv. | — |
| 2026-08-11 | R Michael Carruthers | Director | A | +22,350 deriv. | — |
| 2026-06-24 | Nicholas A Saccomano | President and CEO | Sell | −86 | −$378 |
| 2026-06-24 | Jason A. Leverone | Chief Financial Officer | Sell | −303 | −$1.33K |
| 2026-06-08 | Edward T Mathers | Director | A | +7,650 deriv. | — |
| 2026-06-08 | Valerie Malyvanh Jansen | Director | A | +7,650 deriv. | — |
| 2026-06-08 | Liam Ratcliffe | Director | A | +1,275 deriv. | — |
| 2026-06-08 | Andrew John Phillips | Director | A | +7,650 deriv. | — |
| 2026-06-08 | R Michael Carruthers | Director | A | +7,650 deriv. | — |
| 2026-06-08 | Michael G Grey | Director | A | +7,650 deriv. | — |
| 2026-04-03 | Nicholas A Saccomano | President and CEO | A | +330,000 deriv. | — |
| 2026-04-03 | Dylan Hartley | Chief Scientific Officer | A | +110,000 deriv. | — |
| 2026-04-03 | Samuel Agresta | Chief Medical Officer | A | +110,000 deriv. | — |
| 2026-04-03 | Jason A. Leverone | Chief Financial Officer | A | +110,000 deriv. | — |
| 2026-04-01 | Liam Ratcliffe | Director | A | +15,300 deriv. | — |
| 2026-03-24 | Nicholas A Saccomano | President and CEO | Sell | −86 | −$357 |
| 2026-03-24 | Jason A. Leverone | Chief Financial Officer | Sell | −301 | −$1.25K |
| 2026-01-02 | Isaac Manke | Director | A | +5,258 | — |
| 2026-01-02 | Edward T Mathers | Director | A | +3,911 | — |
| 2025-12-23 | Jason A. Leverone | Chief Financial Officer | Sell | −302 | −$896 |
| 2025-12-23 | Nicholas A Saccomano | President and CEO | Sell | −87 | −$258 |
| 2025-10-02 | Edward T Mathers | Director | A | +4,125 | — |
| 2025-10-02 | Isaac Manke | Director | A | +5,545 | — |
| 2025-09-24 | Nicholas A Saccomano | President and CEO | Sell | −88 | −$231 |
| 2025-09-24 | Jason A. Leverone | Chief Financial Officer | Sell | −303 | −$795 |
| 2025-07-02 | Isaac Manke | Director | A | +6,311 | — |
| 2025-07-02 | Edward T Mathers | Director | A | +4,694 | — |
| 2025-06-25 | Jason A. Leverone | Chief Financial Officer | Sell | −303 | −$722 |
| 2025-06-25 | Nicholas A Saccomano | President and CEO | Sell | −88 | −$210 |
| 2025-05-30 | Isaac Manke | Director | A | +7,650 deriv. | — |
| 2025-05-30 | Michael G Grey | Director | A | +7,650 deriv. | — |
| 2025-05-30 | Valerie Malyvanh Jansen | Director | A | +7,650 deriv. | — |
| 2025-05-30 | R Michael Carruthers | Director | A | +7,650 deriv. | — |
| 2025-05-30 | Andrew John Phillips | Director | A | +7,650 deriv. | — |
| 2025-05-30 | Edward T Mathers | Director | A | +7,650 deriv. | — |
| 2025-05-19 | ACORN CAPITAL ADVISORS GP, LLC | 10%+ Owner | Buy | +1,400,000 | +$2.59M |
| 2025-05-19 | Bihua Chen | — | Sell | −1,813,439 | −$3.36M |
| 2025-05-14 | Cormorant Private Healthcare Fund IV LP | 10%+ Owner | Sell | −24,300 | −$48.24K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| ACORN CAPITAL ADVISORS GP, LLC | 10%+ Owner | 2,839,674 | $9.06M |
| Cormorant Private Healthcare Fund IV LP | 10%+ Owner | 1,813,439 | $5.78M |
| Isaac Manke | Director | 20,583 | $65.66K |
| Jason A. Leverone | Chief Financial Officer | 18,500 | $59.02K |
| Edward T Mathers | Director | 15,310 | $48.84K |
| Nicholas A Saccomano | President and CEO | 11,160 | $35.60K |
| R Michael Carruthers | Director | 4,939 | $15.76K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OKUR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.